CY1125065T1 - Αναστολεις mcl-1 - Google Patents

Αναστολεις mcl-1

Info

Publication number
CY1125065T1
CY1125065T1 CY20221100208T CY221100208T CY1125065T1 CY 1125065 T1 CY1125065 T1 CY 1125065T1 CY 20221100208 T CY20221100208 T CY 20221100208T CY 221100208 T CY221100208 T CY 221100208T CY 1125065 T1 CY1125065 T1 CY 1125065T1
Authority
CY
Cyprus
Prior art keywords
mcl
inhibitors
compounds
methods
present disclosure
Prior art date
Application number
CY20221100208T
Other languages
English (en)
Inventor
Hang CHU
Juan A. Guerrero
Anna E. Hurtley
Tae H. Hwang
Lan Jiang
Darryl Kato
Tetsuya Kobayashi
John E. Knox
Scott E. Lazerwith
Xiaofen Li
David W. Lin
Jonathan W. Medley
Michael L. Mitchell
Devan Naduthambi
Zachary NEWBY
Neil H. SQUIRES
Vickie H. Tsui
Chandrasekar Venkataramani
William J. Watkins
Hong Yang
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1125065T1 publication Critical patent/CY1125065T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα αποκάλυψη γενικώς αφορά σε ενώσεις και φαρμακευτικές συνθέσεις που μπορεί να χρησιμοποιηθούν σε μεθόδους θεραπείας καρκίνου.
CY20221100208T 2018-05-14 2022-03-16 Αναστολεις mcl-1 CY1125065T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671306P 2018-05-14 2018-05-14
US201862749918P 2018-10-24 2018-10-24
PCT/US2019/032053 WO2019222112A1 (en) 2018-05-14 2019-05-13 Mcl-1 inhibitors

Publications (1)

Publication Number Publication Date
CY1125065T1 true CY1125065T1 (el) 2023-06-09

Family

ID=66770559

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100208T CY1125065T1 (el) 2018-05-14 2022-03-16 Αναστολεις mcl-1

Country Status (29)

Country Link
US (4) US10703733B2 (el)
EP (2) EP3793565B1 (el)
JP (3) JP6899975B2 (el)
KR (2) KR102551319B1 (el)
CN (2) CN112118845B (el)
AU (3) AU2019269391B2 (el)
BR (1) BR112020021648A2 (el)
CA (1) CA3099152C (el)
CL (1) CL2020002919A1 (el)
CO (1) CO2020014009A2 (el)
CR (1) CR20200544A (el)
CY (1) CY1125065T1 (el)
DK (1) DK3793565T3 (el)
ES (1) ES2907923T3 (el)
HR (1) HRP20220215T1 (el)
HU (1) HUE057852T2 (el)
IL (2) IL291430B2 (el)
LT (1) LT3793565T (el)
MX (1) MX2020012137A (el)
PE (1) PE20210004A1 (el)
PH (1) PH12020551881A1 (el)
PL (1) PL3793565T3 (el)
PT (1) PT3793565T (el)
SG (1) SG11202010964VA (el)
SI (1) SI3793565T1 (el)
TW (2) TWI719478B (el)
UA (1) UA125163C2 (el)
WO (1) WO2019222112A1 (el)
ZA (1) ZA202007007B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
WO2021005043A1 (en) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN114787139A (zh) 2019-11-26 2022-07-22 吉利德科学公司 用于制备mcl1抑制剂的方法和中间体
JP2023509881A (ja) 2019-12-24 2023-03-10 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
WO2021211922A1 (en) * 2020-04-16 2021-10-21 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
WO2021250102A1 (en) 2020-06-10 2021-12-16 Janssen Pharmaceutica Nv Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
AU2021381769A1 (en) 2020-11-19 2023-06-22 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
WO2022129331A1 (en) 2020-12-17 2022-06-23 Janssen Pharmaceutica Nv Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4330262A1 (en) 2021-04-26 2024-03-06 JANSSEN Pharmaceutica NV Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2023088894A1 (en) 2021-11-16 2023-05-25 Janssen Pharmaceutica Nv Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400610A (zh) 2022-05-04 2024-01-01 美商基利科學股份有限公司 某些ｍｃｌ－１抑制劑之鹽及同質多形體
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
PL3153514T3 (pl) 2004-05-13 2022-01-10 Icos Corporation Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5252635B2 (ja) 2005-07-01 2013-07-31 メダレックス インコーポレーティッド プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
KR20130008021A (ko) 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (ｌｏｘｌ2)에 결합하는 항체, 및 그를 위한 사용 방법
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PT2608809T (pt) 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
TW201427995A (zh) 2012-09-24 2014-07-16 Gilead Sciences Inc 抗ｄｄｒ１抗體
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
KR101709436B1 (ko) 2013-06-14 2017-02-22 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
EP3122353B1 (en) * 2014-03-27 2020-10-28 Vanderbilt University Substituted indole mcl-1 inhibitors
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
EA201790395A1 (ru) 2014-09-26 2017-08-31 Джилид Сайэнс, Инк. Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2017007138A (es) 2014-12-03 2017-08-28 Juno Therapeutics Inc Metodos y composiciones para terapia celular adoptiva.
WO2016100236A2 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
CA2985642A1 (en) 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
US20180161368A1 (en) 2015-05-29 2018-06-14 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
BR112018005295A2 (pt) 2015-09-17 2018-12-11 Novartis Ag terapias com célula t car com eficácia aumentada
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
MA49908A (fr) 2017-08-18 2021-04-28 Amgen Inc Composés inhibant la protéine mcl-1
US11279712B2 (en) 2017-08-29 2022-03-22 Amgen Inc. Macrocyclic compounds that inhibit MCL-1 protein
MA50413A (fr) 2017-10-19 2020-08-26 Amgen Inc Dérivés de benzimidazole et leurs utilisations
EP3762393B1 (en) 2018-03-05 2023-01-11 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
EP3793565B1 (en) 2018-05-14 2022-01-05 Gilead Sciences, Inc. Mcl-1 inhibitors
AU2019271126A1 (en) 2018-05-14 2020-12-10 Reata Pharmaceuticals, Inc. Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
JP2021523200A (ja) 2018-05-15 2021-09-02 ルンドベック ラ ホーヤ リサーチ センター，インク． Ｍａｇｌ阻害剤
EP3826999A1 (en) 2018-07-24 2021-06-02 Epizyme Inc Pyridin-2-one compounds useful as smarca2 antagonists
CN113166173A (zh) 2018-11-09 2021-07-23 普莱鲁德疗法有限公司 作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物
US11498928B2 (en) 2019-01-18 2022-11-15 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as Mcl-1 inhibitors
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN114787139A (zh) 2019-11-26 2022-07-22 吉利德科学公司 用于制备mcl1抑制剂的方法和中间体
JP2021161114A (ja) 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
US20230174496A1 (en) 2020-05-06 2023-06-08 Amgen Inc. Synthesis of Vinylic Protected Alcohol Intermediates
WO2021250102A1 (en) 2020-06-10 2021-12-16 Janssen Pharmaceutica Nv Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
JP2023532592A (ja) 2020-07-08 2023-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状エーテル含有インドール誘導体
AU2021381769A1 (en) 2020-11-19 2023-06-22 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors

Also Published As

Publication number Publication date
WO2019222112A1 (en) 2019-11-21
EP4029868A1 (en) 2022-07-20
PH12020551881A1 (en) 2021-05-31
US20230312490A1 (en) 2023-10-05
ES2907923T3 (es) 2022-04-27
DK3793565T3 (en) 2022-03-07
CR20200544A (es) 2021-02-11
HUE057852T2 (hu) 2022-06-28
PE20210004A1 (es) 2021-01-05
CA3099152C (en) 2023-10-24
AU2019269391A1 (en) 2020-11-19
UA125163C2 (uk) 2022-01-19
EP3793565A1 (en) 2021-03-24
IL291430B1 (en) 2023-12-01
EP3793565B1 (en) 2022-01-05
ZA202007007B (en) 2023-11-29
IL291430A (en) 2022-05-01
AU2021203373A1 (en) 2021-06-24
CN112118845B (zh) 2023-06-13
SG11202010964VA (en) 2020-12-30
US10988451B2 (en) 2021-04-27
WO2019222112A8 (en) 2020-11-12
BR112020021648A2 (pt) 2021-01-26
IL278336B (en) 2022-04-01
KR102551319B1 (ko) 2023-07-05
JP2023060145A (ja) 2023-04-27
CL2020002919A1 (es) 2021-04-16
US11643400B2 (en) 2023-05-09
TW202010740A (zh) 2020-03-16
AU2021203373B2 (en) 2023-09-14
LT3793565T (lt) 2022-02-25
KR20210006981A (ko) 2021-01-19
SI3793565T1 (sl) 2022-04-29
TWI719478B (zh) 2021-02-21
AU2023270332A1 (en) 2023-12-14
JP2021098728A (ja) 2021-07-01
CO2020014009A2 (es) 2020-11-30
US20200331870A1 (en) 2020-10-22
JP6899975B2 (ja) 2021-07-07
US10703733B2 (en) 2020-07-07
HRP20220215T1 (hr) 2022-04-29
US20190352271A1 (en) 2019-11-21
PL3793565T3 (pl) 2022-05-02
CN112118845A (zh) 2020-12-22
TW202122403A (zh) 2021-06-16
JP7240431B2 (ja) 2023-03-15
MX2020012137A (es) 2021-01-29
CN117304130A (zh) 2023-12-29
US20220340535A1 (en) 2022-10-27
TWI813957B (zh) 2023-09-01
AU2019269391B2 (en) 2021-02-25
IL291430B2 (en) 2024-04-01
JP2021515030A (ja) 2021-06-17
CA3099152A1 (en) 2019-11-21
KR20230107889A (ko) 2023-07-18
PT3793565T (pt) 2022-04-13

Similar Documents

Publication Publication Date Title
CY1125065T1 (el) Αναστολεις mcl-1
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
CY1121855T1 (el) Παραγωγα βενζιμιδαζολιου ως αναστολεις βρωμοπεδιου
EA201792348A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
EA201691421A1 (ru) Гетероарилы и их применение
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
CY1124655T1 (el) Κρυσταλλικες μορφες και μορφες αλατος ενωσεων οι οποιες ειναι αγωνιστες του ppar
BR112022008365A2 (pt) Inibidores de cd73
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
CY1122229T1 (el) Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων
EA201791933A1 (ru) Ингибирование активности olig2
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы